Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT02 in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Next Previous
Trial Profile

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT02 in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALN-AAT02 (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Liver disorders
  • Focus Adverse reactions; First in man
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 10 Oct 2020 This trial has been completed in United Kingdom (Date of the global end of the trial: 5 June 2020).
    • 15 Sep 2020 Status changed from active, no longer recruiting to discontinued as the sponsor decided not to proceed with Part B for business reasons. .
    • 06 Apr 2020 According to a Dicerna Pharmaceuticals media release, Dicerna will Lead Global Clinical Development and U.S. Commercialization of Alnylams ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top